Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Study of Etavopivat (FT-4202) in Thalassemia or Sickle Cell Disease
2021-005267-48Phase 2Terminated
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of etavopivat in sickle cell disease (SCD) and Thalassaemia (2 cohorts), sponsored by Forma Therapeutics, Inc. Primary endpoint: Erythroid response and transfusion reduction. Started Aug 2022; status: terminated.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)Thalassaemia
Beyond the preview
Go deeper on 2021-005267-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005267-48.